The relevance of primary tumour location in patients with metastatic colorectal cancer: A meta-analysis of first-line clinical trials

European Journal of Cancer

Volumn 70, Issue , 2017, Pages 87-98

  Holch, Julian Walter ^a   Ricard, Ingrid ^b   Stintzing, Sebastian ^a   Modest, Dominik Paul ^a   Heinemann, Volker ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b UNIVERSITY OF MUNICH   (Germany)

Author keywords

Anti EGFR; Anti VEGF; Bevacizumab; Cetuximab; Metastatic colorectal cancer; Panitumumab; Predictive biomarker; Primary tumour location; Prognostic biomarker; Sidedness

Indexed keywords

BEVACIZUMAB; CAPECITABINE; CETUXIMAB; FLUOROURACIL; FOLINIC ACID; GIMERACIL PLUS OTERACIL POTASSIUM PLUS TEGAFUR; IRINOTECAN; MITOMYCIN; OXALIPLATIN; PANITUMUMAB; VASCULOTROPIN INHIBITOR; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR; MONOCLONAL ANTIBODY; VASCULOTROPIN A;

ARTICLE; CANCER CHEMOTHERAPY; CANCER LOCALIZATION; HUMAN; META ANALYSIS; METASTATIC COLORECTAL CANCER; OVERALL SURVIVAL; PHARMACOGENETICS; PREDICTIVE VALUE; PRIMARY TUMOR; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); TREATMENT RESPONSE; ANTAGONISTS AND INHIBITORS; COLORECTAL NEOPLASMS; PATHOLOGY; PROGNOSIS; RETROSPECTIVE STUDY; SURVIVAL ANALYSIS;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COLORECTAL NEOPLASMS; HUMANS; PROGNOSIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECEPTOR, EPIDERMAL GROWTH FACTOR; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84999098883     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2016.10.007     Document Type: Article

References (33)

1. [1] Missiaglia, E., Jacobs, B., D'Ario, G., Di Narzo, A.F., Soneson, C., Budinska, E., et al. Distal and proximal colon cancers differ in terms of molecular, pathological, and clinical features. Ann Oncol 25:10 (2014), 1995–2001.
2. [2] Yamauchi, M., Lochhead, P., Morikawa, T., Huttenhower, C., Chan, A.T., Giovannucci, E., et al. Colorectal cancer: a tale of two sides or a continuum?. Gut 61:6 (2012), 794–797.
3. [3] Yamauchi, M., Morikawa, T., Kuchiba, A., Imamura, Y., Qian, Z.R., Nishihara, R., et al. Assessment of colorectal cancer molecular features along bowel subsites challenges the conception of distinct dichotomy of proximal versus distal colorectum. Gut 61:6 (2012), 847–854.
4. [4] Carethers, J.M., One colon lumen but two organs. Gastroenterology 141:2 (2011), 411–412.
5. [5] Bufill, J.A., Colorectal cancer: evidence for distinct genetic categories based on proximal or distal tumor location. Ann Intern Med 113:10 (1990), 779–788.
6. [6] LaPointe, L.C., Dunne, R., Brown, G.S., Worthley, D.L., Molloy, P.L., Wattchow, D., et al. Map of differential transcript expression in the normal human large intestine. Physiol Genomics 33:1 (2008), 50–64 Epub 2007 Dec 4.
7. [7] Iacopetta, B., Are there two sides to colorectal cancer?. Int J Cancer 101:5 (2002), 403–408.
8. [8] Guinney, J., Dienstmann, R., Wang, X., de Reynies, A., Schlicker, A., Soneson, C., et al. The consensus molecular subtypes of colorectal cancer. Nat Med 21:11 (2015), 1350–1356.
9. [9] Bendardaf, R., Buhmeida, A., Hilska, M., Laato, M., Syrjanen, S., Syrjanen, K., et al. VEGF-1 expression in colorectal cancer is associated with disease localization, stage, and long-term disease-specific survival. Anticancer Res 28:6B (2008), 3865–3870.
10. [10] Benedix, F., Kube, R., Meyer, F., Schmidt, U., Gastinger, I., Lippert, H., Comparison of 17,641 patients with right- and left-sided colon cancer: differences in epidemiology, perioperative course, histology, and survival. Dis Colon Rectum 53:1 (2010), 57–64.
11. [11] Boisen, M.K., Johansen, J.S., Dehlendorff, C., Larsen, J.S., Osterlind, K., Hansen, J., et al. Primary tumor location and bevacizumab effectiveness in patients with metastatic colorectal cancer. Ann Oncol 24:10 (2013), 2554–2559.
12. [12] Modest, D.P., Schulz, C., von Weikersthal, L.F., Quietzsch, D., von Einem, J.C., Schalhorn, A., et al. Outcome of patients with metastatic colorectal cancer depends on the primary tumor site (midgut vs. hindgut): analysis of the FIRE1-trial (FuFIRI or mIROX as first-line treatment). Anticancer Drugs 25:2 (2014), 212–218.
13. [13] von Einem, J.C., Heinemann, V., von Weikersthal, L.F., Vehling-Kaiser, U., Stauch, M., Hass, H.G., et al. Left-sided primary tumors are associated with favorable prognosis in patients with KRAS codon 12/13 wild-type metastatic colorectal cancer treated with cetuximab plus chemotherapy: an analysis of the AIO KRK-0104 trial. J Cancer Res Clin Oncol 140:9 (2014), 1607–1614.
14. [14] Price, T., Buizen, L., Hardingham, J., Lee, C., Townsend, A., Molecular subgroups from the AGITG MAX trial; right or left primary site of colorectal cancer and outcomes for metastatic colorectal cancer (mCRC). Ann Oncol 25:suppl 4 (2014), iv167–iv209 EMSO 2014. Abstract 511P 2014. http://dx.doi.org/10.1093/annonc/mdu333.
15. [15] Seligmann, J., Elliott, F., Richman, S., Southward, K., Barrett, J., Quirke, P., et al. Primary tumour location (PTL) as a prognostic and predictive factor in advanced colorectal cancer: data from 2075 patients in randomised trials. Ann Oncol 25:Suppl. 4 (2014), iv167–iv209.
16. [16] Loupakis, F., Yang, D., Yau, L., Feng, S., Cremolini, C., Zhang, W., et al. Primary tumor location as a prognostic factor in metastatic colorectal cancer. J Natl Cancer Inst, 107(3), 2015 (pii):dju427.
17. [17] Zhang, Y., Ma, J., Zhang, S., Deng, G., Wu, X., He, J., et al. A prognostic analysis of 895 cases of stage III colon cancer in different colon subsites. Int J Colorectal Dis 30:9 (2015), 1173–1183.
18. [18] Sunakawa, Y., Ichikawa, W., Tsuji, A., Denda, T., Segawa, Y., Negoro, Y., Prognostic impact of primary tumor location on survival time in patients (pts) with metastatic colorectal cancer (mCRC) treated with cetuximab plus oxaliplatin-based chemotherapy: a subgroup analysis of the JACCRO CC-05/06. ASCO-GI 2016 Abstr 613, 2016.
19. [19] Outcome in CALGB 80405. Presenter: H. Lenz https://cslide.ctimeetingtech.com/library/esmo/browse/search/p#2z95y02nD [Special session, ESMO 2016 Congress, 10/10/2016].
20. [20] Schrag, D., Weng, S., Brooks, G., Meyerhardt, J., Venook, A., The relationship between primary tumor sidedness and prognosis in colorectal cancer. J Clin Oncol, 34, 2016 (Suppl; abstr 3505) 2016.
21. [21] Tejpar, S., Stintzing, S., Ciardiello, F., Tabernero, J., Van Cutsem, E., Beier, F., et al. Prognostic and predictive relevance of primary tumor location in patients with RAS wild-type metastatic colorectal cancer: retrospective analyses of the CRYSTAL and FIRE-3 trials. JAMA Oncol, 2016, 10.1001/jamaoncol.2016.3797.
22. [22] Wang, F., Bai, L., Liu, T.S., Yu, Y.Y., He, M.M., Liu, K.Y., et al. Right-sided colon cancer and left-sided colorectal cancers respond differently to cetuximab. Chin J Cancer 34:9 (2015), 384–393, 10.1186/s40880-015-0022-x.
23. [23] Brule, S.Y., Jonker, D.J., Karapetis, C.S., O'Callaghan, C.J., Moore, M.J., Wong, R., et al. Location of colon cancer (right-sided versus left-sided) as a prognostic factor and a predictor of benefit from cetuximab in NCIC CO.17. Eur J Cancer 51:11 (2015), 1405–1414.
24. [24] Chen, K.H., Shao, Y.Y., Chen, H.M., Lin, Y.L., Lin, Z.Z., Lai, M.S., et al. Primary tumor site is a useful predictor of cetuximab efficacy in the third-line or salvage treatment of KRAS wild-type (exon 2 non-mutant) metastatic colorectal cancer: a nationwide cohort study. BMC Cancer, 16(1), 2016, 327.
25. [25] He, W.-Z., Yang, Q., Jiang, C., Liao, F.-X., Liu, S.-S., Xia, L.-P., Bevacizumab effectiveness and primary tumor location in metastatic colorectal cancer patients. J Clin Oncol, 34, 2016 (Suppl. 4S; abstr 683) 2016.
26. [26] Moretto, R., Cremolini, C., Rossini, D., Pietrantonio, F., Battaglin, F., Mennitto, A., et al. Location of primary tumor and benefit from anti-epidermal growth factor receptor monoclonal antibodies in patients with RAS and BRAF wild-type metastatic colorectal cancer. Oncologist 21:8 (2016), 988–994 http://dx.doi.org/10.1634/theoncologist.2016-0084. [Epub 2016 Jul 5].
27. [27] Wong, H.-L., Field, K., Lomax, A., Tacey, M., Shapiro, J., McKendrick, J., et al. Impact of tumor site on bevacizumab (BEV) efficacy in metastatic colorectal cancer (mCRC). J Clin Oncol, 32, 2014 (Suppl; abstr e14558) 2014.
28. [28] He, W.Z., Xia, L.P., RE: primary tumor location as a prognostic factor in metastatic colorectal cancer. J Natl Cancer Inst, 107(9), 2015.
29. [29] Outcome according to Left vs. Right side in the panitumumab studies. Presenter: M. Peeters https://cslide.ctimeetingtech.com/library/esmo/browse/search/p#2z95y02nA [Special session, ESMO 2016 Congress, 10/10/2016].
30. [30] Lenz, H.-J., Lee, F.-C., Yau, L., Koh, H., Knost, J., Mitchell, E., et al. MAVERICC, a phase 2 study of mFOLFOX6-bevacizumab (BV) vs FOLFIRI-BV with biomarker stratification as first-line (1L) chemotherapy (CT) in patients (pts) with metastatic colorectal cancer (mCRC). J Clin Oncol, 34, 2016 (Suppl. 4S; abstr 493) 2016.
31. [31] Pro Discussion. Presenter: D. Arnold https://cslide.ctimeetingtech.com/library/esmo/browse/search/p#2z95y02nE [Special session, ESMO 2016 Congress, 10/10/2016].
32. [32] Boeckx, N., Toler, A., Op de Beeck, K., Kafatos, G., Deschoolmeester, V., Rolfo, C., et al. Primary tumor sidedness impacts on prognosis and treatment outcome: results from three randomized studies of panitumumab plus chemotherapy versus chemotherapy or chemotherapy plus bevacizumab in 1 and 2 line RAS/BRAF WT mCRC. Ann Oncol, 27(Suppl 6), 2016 Abstr 89P, ESMO 2016.
33. [33] Outcome according to Left vs. Right side in the FOLFIRI cetuximab and FIRE 3 study. Presenter: V. Heinemann. https://cslide.ctimeetingtech.com/library/esmo/browse/search/bcc#2z95y02nB [Special session, ESMO 2016 Congress, 10/10/2016].